IGC Pharma Reveals New Phase 2 Interim Findings Showcasing Cognitive Advantages of IGC-AD1 in Alzheimer’s Therapy.

Menarini Group showcases new and updated findings at the 2024 San Antonio Breast Cancer Symposium, emphasizing the importance of ORSERDU® (Elacestrant).

Innovent has announced that SINTBILO® is being included for the first time in China’s National Reimbursement Drug List, along with a new indication for Olverembatinib.

Akeso has announced that Cadonilimab and Ivonescimab are now part of China's national list for reimbursed drugs.

Lecanemab, marketed as LEQEMBI®, has been introduced for Alzheimer's disease treatment in South Korea.

Kelun-Biotech's TROP2 ADC, sacituzumab tirumotecan (sac-TMT), has received marketing authorization from China's NMPA for the treatment of second-line or later advanced metastatic TNBC.

According to a report by Yole Développement, the CRISPR technology market is projected to reach $5 billion by 2023.

Replimune has been granted Breakthrough Therapy status for RP1 and has filed a Biologics License Application for RP1 with the FDA via the Accelerated Approval Pathway.

OncoVerity Raises Additional Series A Funds to Progress Cusatuzumab for Newly Diagnosed AML.

Vicebio Moves Forward with Clinical Trials for RSV/hMPV Bivalent Vaccine and Enhances Board by Appointing Industry Experts.

Jazz Pharmaceuticals has received U.S. FDA approval for Ziihera® (zanidatamab-hrii) to treat adults with HER2-positive (IHC 3+) biliary tract cancer (BTC).

Avirmax Biopharma Reports Dosing of First Patient in ABI-110 Clinical Study, a Novel Gene Therapy for Wet AMD with PCV.